Lepirudin

Summary

Lepirudin is a recombinant analogue of hirudin, a peptide that directly inhibits thrombin. It belongs to the antithrombotic peptide family and has been used intravenously to treat heparin‑induced thrombocytopenia (HIT) and related thrombotic complications. Although once marketed under the name Refludan, it has been withdrawn from commercial availability but remains referenced in clinical guidelines as a non‑heparin anticoagulant option for patients with normal renal function.

Mechanism of Action

Lepirudin binds to the active site of thrombin, blocking its ability to cleave fibrinogen into fibrin and to activate other coagulation factors and platelets. By occupying both the catalytic pocket and exosite I of thrombin, it prevents thrombin‑mediated clot formation without requiring antithrombin as a cofactor, distinguishing it from heparin‑based agents. This direct inhibition halts the propagation of the coagulation cascade at a late stage, providing anticoagulation in settings where heparin cannot be used.

What the Research Shows

Guidelines from the American College of Chest Physicians recommend lepirudin as a preferred non‑heparin anticoagulant for HIT patients with normal renal function, alongside argatroban and danaparoid. Reviews of direct thrombin inhibitors describe lepirudin’s kinetic profile and clinical use, noting it as one of three agents approved for such indications. Clinical discussions of HIT emphasize lepirudin as an alternative to heparin, with dosing individualized based on renal status. The literature consistently positions lepirudin within the therapeutic armamentarium for immune‑mediated HIT, though it notes the need for further comparative studies with newer agents.

Reported Benefits

Evidence from guideline panels and specialist reviews indicates that lepirudin provides effective anticoagulation in HIT, particularly when renal function is preserved, reducing the risk of thrombotic complications without relying on antithrombin. Its direct thrombin inhibition offers a mechanistically distinct approach compared with heparin, making it useful when heparin antibodies are present. Clinical use has been associated with successful management of HIT‑related thrombosis in several reported settings.

Limitations of the Evidence

Lepirudin has been withdrawn from the market, limiting its practical availability. The cited guidelines assign it a Grade 2C recommendation, reflecting limited high‑quality comparative data. Evidence is largely based on expert consensus and observational experience rather than large randomized trials, and its role relative to newer agents such as fondaparinux or oral anticoagulants remains uncertain. Renal impairment restricts its use, and no definitive dosing protocols are provided in the abstracts.

Safety Considerations

As a potent anticoagulant, lepirudin carries a risk of bleeding, a common concern for all direct thrombin inhibitors. The guidelines advise its use only in patients with normal renal function, implying renal clearance and potential accumulation in renal insufficiency. No specific adverse event rates are detailed in the abstracts, but caution is advised when transitioning to warfarin, as premature overlap can precipitate coumarin‑induced necrosis. Monitoring of coagulation parameters is recommended during therapy.

How It Is Administered

Lepirudin is administered intravenously as a sterile solution. Dosing is typically individualized based on patient weight, renal function, and therapeutic response, with continuous infusion often employed to maintain target anticoagulation levels. The formulation is supplied for parenteral use only and requires aseptic handling in clinical settings.

Routes of Administration

Goals & Uses

• Prevention of thromboembolic eventsPreventiveModerate
• Alternative anticoagulation in heparin-allergic patientsHematologyModerate
• Prevention of thromboembolic complications in HIT with thrombosisHematology / ThrombosisHigh
• Anticoagulation in heparin-induced thrombocytopenia (HIT)Hematology / ThrombosisHigh
• AnticoagulationTherapeuticHigh

Contraindications

• Recent major surgerySurgicalModerate
• Hypersensitivity to hirudins or lepirudinAllergy / ImmunologyHigh
• Active major bleedingHemorrhagic RiskHigh
• Severe renal impairmentOrganHighKidney function concerns
• Bacterial endocarditisInfectious / CardiovascularModerate
• Severe uncontrolled hypertensionCardiovascularModerate
• Recent major surgery or organ biopsySurgicalHigh
• Active bleedingHemostasisHigh

Adverse Effects

• Allergic reactionsImmunologicalRare
• Injection site reactionsLocalUncommon
• HypotensionCardiovascularUncommonLow blood pressure
• Anaphylaxis / hypersensitivity reactionsImmunologyUncommon
• BleedingHematologicCommonAbnormal bleeding or hemorrhage
• FeverSystemicUncommonElevated body temperature
• Anti-hirudin antibody formationImmunologyCommon
• Bleeding (hemorrhage)HematologyCommon
• Renal function changesRenalUncommon

Drug Interactions

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants)High
• Warfarin and other vitamin K antagonistsHigh
• Antiplatelet agents (e.g., aspirin, clopidogrel)Moderate
• Thrombolytics (e.g., alteplase, streptokinase)High
• NSAIDsModerateMay increase renal risk in susceptible patients
• Antiplatelet agents (e.g., aspirin, clopidogrel, GPIIb/IIIa inhibitors)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentAbsolute
• Pediatric patientsAgeRelative
• Patients with prior lepirudin exposureImmunologyRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionWithdrawnApproved: Heparin‑induced thrombocytopeniaMarketing authorisation withdrawn in 2012.
• United StatesUnapprovedNever received FDA approval.
• United KingdomWithdrawnApproved: HITFormerly approved, now withdrawn.

Approved in the EU (2000) for HIT; never approved in the United States. Withdrawn from commercial availability in many regions after safety concerns and availability of newer agents.

Evidence & Sources

• Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
  Journal ArticleModerateLinkins LA, et al.2012-01-01T00:00:00.000000Z
• Direct thrombin inhibitors
  Journal ArticleModerateKaplan KL, Francis CW2002-01-01T00:00:00.000000Z
• Heparin-induced thrombocytopenia
  Journal ArticleModerateBambrah RK, et al.2011-01-01T00:00:00.000000Z
• Heparin-induced thrombocytopenia
  Journal ArticleModerateWarkentin TE2007-01-01T00:00:00.000000Z

Frequently Asked Questions